OMass Therapeutics is Expanding its Team

November 20, 2018

Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is expanding and building out its expert team. We value collaboration, continuous learning, free-thinking and innovation at all levels of our company. Our modern headquarters are located in Oxford, an area famous for scientific research and discovery.

Our current vacancies include:
Protein biochemists for purification and expression of membrane-bound and soluble proteins
Mass spectrometrists with experience of native MS
Computational chemists
Bioinformaticians

OMass is developing novel medicines using its suite of proprietary technologies based on high-resolution mass spectrometry of intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation. These platforms are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs.

To find out more please visit the careers section of our website at www.omass.com/careers.

Further information:

JW Communications +44 (0)7818430877
Julia Wilson juliawilsonuk@gmail.com

Notes for Editors:

About OMass Therapeutics

OMass Therapeutics is a private biotechnology company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at: www.omass.com.

Back To News

Related News

OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
July 28, 2020

Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies…

Read More
OMass Announces Publication in Nature Methods
May 15, 2020

Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high…

Read More
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
February 25, 2020

– OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton – Oxford, 25 February 2020 – OMass Therapeutics…

Read More
OMass Therapeutics Announces £27.5 Million Extended Series A Financing
February 17, 2020

– Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders – Oxford, 17 February 2020 –…

Read More